– Funding secured, extending the financial runway to reach a proof-of-concept inflection point – Company’s attractiveness reinforced through the onboarding of new investors LILLE, France & PARIS–(BUSINESS WIRE)–4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a … [Read more…]

  LOS ANGELES–(BUSINESS WIRE)–Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) today reported preliminary financial results for the fourth quarter and year ended December 31, 2025. “I want to congratulate our employees on a year of many accomplishments. We returned to total revenue growth in the last three quarters of the year, driven by our corporate channel … [Read more…]

Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 On Track to File an Investigational New Drug Application (IND) … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #AACRIO—Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled … [Read more…]

US$46 million investment to establish wholly owned Puerto Rico subsidiary supporting U.S. manufacturing, supply security, and long-term growth of BESREMi® (ropeginterferon alfa-2b) Company plans to obtain regulatory approval and commence operations at its Puerto Rico manufacturing facility in 2027 BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise … [Read more…]

The Pistons’ first-ever partnership with a men’s health company will be showcased at the top of the Pistons’ backboard, a prime in-arena spot AUSTIN, Texas–(BUSINESS WIRE)–Rugiet, a men’s healthcare platform, today announced its designation as the official men’s Rx partner for the Detroit Pistons. The partnership marks the franchise’s first-ever collaboration in men’s health and … [Read more…]

Collaboration combines Ethris’ proprietary technology platforms with DZIF’s infectious disease research expertise to advance mRNA-based vaccines across a broad range of pathogens Agreement enables manufacturing of mRNA vaccine material by Ethris’ partners Patheon and Evonik for DZIF-led vaccine research & development MUNICH–(BUSINESS WIRE)–Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and … [Read more…]

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential to help save hundreds of thousands of lives in the US alone eyonis® LCS is the only device capable of both detecting and characterizing lung cancer in … [Read more…]

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing disability progression in PPMS – – Fenebrutinib numerically reduced the risk of disability progression by 12% compared to Ocrevus as early as 24 weeks; additional analysis showed … [Read more…]

OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsi Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platformii,iii,iv,v IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic … [Read more…]